Core Viewpoint - CytomX Therapeutics (CTMX) shows potential due to its masked antibody program, leading to a "Buy" sentiment from analysts [1] Group 1: Company Overview - The company is focused on developing innovative therapies, particularly in the field of masked antibodies, which could provide significant therapeutic advantages [1] Group 2: Analyst Insights - The analyst expresses optimism based on the promise of CytomX's technology and emphasizes the importance of understanding the science behind biotech investments [1]